Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

CNS tumours

4169 - Treatment of Recurrent Glioblastoma (GB) after Radiotherapy (RT) and Temozolomide (TMZ): A retrospective analysis of the GLIOCAT study

Date

09 Sep 2017

Session

CNS tumours

Presenters

Miguel Gil

Citation

Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366

Authors

M. Gil1, J.M. Velarde2, M. Martinez-Garcia3, O. Gallego4, S. del Barco5, E. Pineda6, C. Mesia7, A. Estival8, N. Vilariño3, J. Marruecos5, E. Verger9, J. Craven10, R. Fuentes11, A. Lucas12, M. Macià13, C. Carrato14, N. Vidal15, R. Velasco16, S. Villa17, C. Balana18

Author affiliations

  • 1 Medical Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, 08907 - Barcelona/ES
  • 2 Biostatistics, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 3 Medical Oncology Department, Hospital del Mar, Barcelona/ES
  • 4 Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 5 Medical Oncology Department, ICO-Girona, Girona/ES
  • 6 Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 7 Medical Oncology Department, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 8 Medical Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 9 Radiation Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona/ES
  • 10 Radiation Oncology Department, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 11 Radiation Oncology Department, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 12 Radiation Oncology, Institut Català d'Oncologia, L'Hospitalet de Llobregat, 08907 - Barcelona/ES
  • 13 Radiation Oncology Department, Institut Català d'Oncologia, L'Hospitalet de Llobregat, 08907 - Barcelona/ES
  • 14 Pathology, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 15 Pathology, Hospital Universitari de Bellvitge, 08907 - L'Hospitalet/ES
  • 16 Neuro-oncology, Institut Catala de Oncologia, 8907 - Barcelona/ES
  • 17 Radiation Oncology, Hospital Universitari Germans Trias i Pujol, Fundació Institut d' Investigacions en Ciencies de la Salut Germans Trias i Pujol, Catalan Institute of Oncology Badalona, 08916 - Badalona/ES
  • 18 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
More

Resources

Abstract 4169

Background

There is no standard treatment in recurrent GB and overall survival (OS) ranges from 3 to 9 months (m). The aim of this study was to identify clinical or biological factors that guide the best therapeutic strategy.

Methods

We identified 397 patients (Pts) from GLIOCAT database (432 patients uniformly treated with Stupp’s regimen) who had recurrent GB: 250 Pts received 1 or more active treatment (TT) and 147 Pts didn’t. We analysed clinical and molecular characteristics, treatments received, OS and progression-free survival (PFS).

Results

The median TT lines after recurrence was 1 (0-5). At 1st recurrence surgery was performed in 51 (30 alone), RT in 8 and systemic therapy (ST) in 208 Pts (189 without any local TT): Bevazicumab (BV) ± Irinotecan (IR) 90; clinical trial (CT) 42; TMZ 27; Nitrosoureas (NU) 27]. Pts without any TT were older (p 

Conclusions

Pts who received TT at recurrence offered a better OS in multivariate analysis. Pts undergoing surgery did not present better OS than those who only received ST. MGMT methylation is not a predictor of better OS in recurrence. Pts treated with BV had longer PFS but not OS.

Clinical trial identification

Legal entity responsible for the study

GLIOCAT

Funding

None

Disclosure

M. Gil-Gil: Membership on a Roche advisory board.

\r\n

All other authors have declared no conflicts of interest.

Disclosure

M. Gil-Gil: Membership on a Roche advisory board.

All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.